Cost-Related Issues And Availability Of Older Drugs For Management Of Schizophrenia
Schizophrenia is a severe mental disorder that affects approximately 0.7% of the world’s population. I have been fascinated with schizophrenia, my hold life, every person I’ve ever met with schizophrenia I felt an instant bond with and loved. I never once saw them as crazy, but just misunderstood. KEEP GOING
Management of schizophrenia requires a polypharmacological approach whereby a wide array of drugs are used to ensure that the symptoms are managed (Freudenreich pp. 157-170). The success of the management process requires that vigilance is applied and that successful measures are implemented to successfully treat and control the symptoms. Qualitatively, there is always the need to successfully implement a useful drug therapy in the management and control of the somatic symptoms (Horvitz-Lennon et al., pp. 421-426). In healthcare settings, schizophrenia is known to cause various impacts and challenges that reduce the quality and issues associated with the symptoms as they present in the clients (Freudenreich pp. 157-170). Modern drugs for the management of schizophrenia include the antipsychotics and other medications that stabilize the mood and affect to assist in the control of the negative outcomes that may be bad for the patients. In a successful manner, there is a need to promote a good and competitive approach to management. Older drugs for management of schizophrenia should be more available than the newer ones because they are cheaper and efficient as opposed to the newer ones
The cost of medications determines the outcomes of healthcare since the affordability is an issue. Schizophrenia is a condition that requires progressive management to assist in controlling the challenges while working on approaches to reduce the adversities (Freudenreich pp. 157-170). In a comprehensive and best approach, the need to successfully implement best and effective interventions is useful in an approach and integrated measure to control the cost-related issues. The modern medications deployed in the management of schizophrenia cost approximately $3800-$5,300 annually, which is high (Revicki, pp. S101-S109). For the mentally ill, there is always the need for relatively cheap healthcare costs to assist in integrated and quality management of the conditions. The following research is an exploration of the cost-related issues in older drugs for the management of schizophrenia since they are not available (Freudenreich pp. 157-170). The modern drugs are more common, and it is not helpful since the individuals are not benefitting from the process hence the need to successfully implement best and comprehensive measures for controlling the negative and adversities associated with the plight of the individuals in the healthcare setting. Older drugs for management of schizophrenia should be more available than the newer ones because they are cheaper and efficient as opposed to the newer ones.
Background/Summary of the issue
Schizophrenia, for a long time, has proven to be a mental illness that is mostly found in all over the world in all races, social classes and cultures. The psychiatric clinics have been trying to find suitable solutions to cushion the affected individuals and enhance a good management plan as needed (Zeller, Scott, and Leslie, pp. 165). The success of the integrated approaches always focuses on best and effective measures as needed. The main challenge is on the cost of the medications since individuals affected by the conditions have huge annual expenditures to provide solutions to the challenge. Based on the applied protocols, there is the need to work on best and effective measures as per the applied protocols (Freudenreich pp. 157-170). Necessarily, there is a need to ensure that an effective and best intervention is applied for the promotion of best and cheaper alternatives.
The old drugs for management of the schizophrenia, including the antibiotics prescribed for the same, are considered rare alternatives with regards to the condition. Availability of the medication is an issue that is worth looking into since most of the patients cannot have stable and good access to the medications hence making the situation worse (Zeller, Scott, and Leslie, pp. 165). Necessarily, it is good to enhance a good approach and strategic intervention in controlling the challenges while working on measures as per the applied protocols. It is difficult to find old drugs such as antibiotics and the ones used in conventional medicine since they are cheap (Freudenreich pp. 157-170). The main paradox is in the availability of the drugs while their relative cost is cheaper, and therefore deployment process is good and fundamental in the promotion of the best and effective approach for mitigation of challenges. Some of the best and necessary control protocols with regards to the cost-effectiveness of the patients. It is good to focus on the best and effective protocol and ensure that the patients get the best medication and management.
Common medications deployed include Fluphenazine, Haloperidol, Perphenazine, and Chlorpromazine (Zeller, Scott, and Leslie, pp. 165). Based on the applied protocols and interventions, it is necessary to apply the cheapest choices for the clients to have affordable and quality care rather than the choices and deployed interventions and drugs that are difficult to adapt. There are challenges in the critical management of the patients, and it is useful to ensure that the cost of care is alleviated (Freudenreich pp. 157-170). Pharmacological deficiency is an issue and a challenge associated with the drugs used for the management of schizophrenia, and the best method is, therefore, to formulate a good protocol in an application of the most conventional and effective approaches in mitigation of challenges and effective implementation as necessary. Necessarily, it is good to ensure that a cheaper alternative is applied. The old antipsychotics such as Aripiprazole, Asenapine, Lurasidone, and Quetiapine are cheaper, but it is difficult to find them in the market since they are regarded as atypical (Zeller, Scott, and Leslie, pp. 165). The challenge spans in healthcare, whereby effective and desired medications are not deployed to alleviate the economic burden on the people. It is, therefore, an issue that is being looked into to facilitate a good approach and fundamental strategy for elimination of challenges and working on measures to promote the best and fundamental approach for quality and applied approaches as per the policies and issues implemented.
Overview of the research
The research is a critical review of the schizophrenia management techniques and applied methods to facilitate the best and comprehensive measures of success and integration of the cheap methods such as the drugs (Freudenreich pp. 157-170). Pharmacologic solutions and approaches to quality management of schizophrenia are explored as possible solutions to the problems at hand. Consideration of best and integrated approaches are regarded as key and effective in the elimination of adversities while working on possible solutions to be deployed and used in facilitating nothing but the best approach. The approach, therefore, employs a critical and best intervention in the elimination of challenges while working on perfect and best measures as needed. Necessarily, there is the need to focus on the production methods and approvals of the drugs into the market (Freudenreich pp. 157-170). Expected results are supposed to be associated with the production process and other critical issues that are associated with the allowed alternatives. It is always in order to assist in an integrated and quality protocol for mitigation of the cost-related issues that bar the good production of useful medications.
The scarcity of the older drugs for management of schizophrenia is looked it critically by considering possible options such as manufacturer restrictions and the reduced production rates. Usually, it is in order to focus on the production approaches and measures of success for quality and fundamental processes (Takada, Kazuhiko, and Toshifumi, pp. 2541). Necessarily, it is useful to apply some of the best and perfect interventions to focus on the best and effective approaches as needed. A successful approach is needed to ensure that quality and best methods are applied for the best and comprehensive approach as needed. The success of the protocols is good for the mitigation of challenges and making the drugs available in the market. The manufacturer’s opinion regarding the old and therapeutic drugs is considered so that a good and effective approach is deployed to ensure that the best and comprehensive measures are deployed (Zeller, Scott, and Leslie, pp. 165). Necessarily, a quality and comprehensive measure are effective in controlling the challenges while working on a perfect and key approach to the reduction of the challenges and reduce the effectiveness of the healthcare processes. Necessarily, there is always the need to focus on an integrated protocol and promotion of a competitive and best approach to mitigate the challenges (Kondej, Piotr, and Agnieszka, pp. 3105). Necessarily, the best and effective approach requires that effective measures and approaches are implemented and controlled for best and effective integrative protocols.
Counterargument
Although the obvious reasons for the missing older drugs for management of schizophrenia such as manufacturer prioritization of the new drugs, the atypical nature and scientific research recommendation of the newer drugs, there are arguments that they are not the real causes of the shortage. Some people relate the shortages to embezzlement of funds, lack of seriousness of the health sector in the integration of the old drugs and patient preferences. The counterargument is not true since the supply of the drugs is the main issue. With the increased cost of healthcare, the challenges are associated with increased cost of drugs for managing schizophrenia. The older drugs should be made available to support the economic shortages of the patients as opposed to the newer drugs.
Although the research is supporting the reuse of old drugs for management of schizophrenic drugs, most of the people will find it necessary to contradict the overall approach and measure since it is an issue that may be contrary to the modern developments in medicine (Horvitz-Lennon et al., pp. 421-426). The success of the approaches and interventions require that perfect and key interventions and approaches are implemented to assist in a controlled approach and mitigation of challenges as well. The researches are seeking to find relief and solutions to the patients who have economic problems by exploring the positive aspects such as the availability of the medications. It is necessary to apply some of the best and effective measures to assist in the mitigation of challenges while working on perfect measures to control the native and other challenges that reduce the compliance to the modern medications (Freudenreich pp. 157-170). The research is focused on finding economical solutions to the most vulnerable populations in the society, especially with economic problems, and therefore accessing the effective and necessary protocols is a key and necessary issue to be deployed for a successful and higher quality integration.
Conclusion
Based on this research I would argue that KEEP GOING
When the patients pay medical bills that are higher, it is not recommended, and the research seeks to find alternatives that make the entire process feasible and higher quality as well. An integrated and quality approach is always focused on the mitigation of challenges while implementing the best and comprehensive approach as per the identified strategies. Necessarily, there is a need to ensure and foster a competitive and best protocol. Quality and effective measures are always based on the protocols and interventions with cheaper and more useful schizophrenic drugs. The research also is essential since it can be used by the manufacturers to change their trends and manufacture the best drugs that are cheap and can be deployed in the market to attain stability and effectiveness of the identified protocols as needed.
Works Cited
Freudenreich, Oliver. “Treatment-Resistant Schizophrenia.” Psychotic Disorders. Humana, Cham, 2020. 157-170.
Horvitz-Lennon, Marcela, et al. “The role of antipsychotic plasma levels in the treatment of schizophrenia.” American Journal of Psychiatry 174.5 (2017): 421-426.
Kondej, Magda, Piotr Stępnicki, and Agnieszka A. Kaczor. “Multi-target approach for drug discovery against schizophrenia.” International journal of molecular sciences 19.10 (2018): 3105.
Revicki, Dennis A. “Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.” Schizophrenia research 35 (1999): S101-S109.
Takada, Ryohei, Kazuhiko Yamamuro, and Toshifumi Kishimoto. “Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia.” Neuropsychiatric disease and treatment 14 (2018): 2541.
Zeller, Scott L., and Leslie Citrome. “Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting.” Western Journal of Emergency Medicine 17.2 (2016): 165.